The release of the FDA’s draft guidance on psychedelic research marks a significant milestone in mental health treatment. The 14-page document provides researchers with a comprehensive framework to conduct studies on psychedelic drugs, which have shown initial promise in treating mood, anxiety, and substance use disorders. Covering various aspects of drug development, the guidance offers insights into trial conduct, data collection, subject safety, and new drug application requirements. By outlining the unique challenges inherent in designing psychedelic drug development programs, the FDA aims to assist researchers in designing studies that yield reliable and interpretable results, supporting future drug applications.
Let me put it another way: the United States government spent more than fifty years…
New Jersey’s THC beverage market is heading into the most consequential stretch of its short…
Mormon Wives star Mikayla Matthews says medical cannabis was “literally life-changing” for her nerve pain…
Chains reorder every two weeks and earn twice the discounts. Independents stock the same breadth…
We head to Canna Country Farms in Humboldt for Legendary Strains to discover the Ocimene…
Cannabis advocates should take the lesson here too. The industry doesn't need to inflate its…